We’re proud to share that Potter Clarkson has once again been ranked among the world’s leading patent firms in the IAM Patent 1000: The World’s Leading Patent Professionals 2025.
On 1 January 2025, a new and modernised Swedish Patent Act entered into force, replacing the Patent Act from 1967.
Formula 1 is on the cusp of a significant transformation, with the sport considering drastic changes for its next set of engine regulations. Ethan Silverstone, patent attorney and former F1 engineer, considers the strategic IP decisions going on behind the scenes.
The implementation of the Windsor Framework on 1 January 2025 marked a significant turning point in the UK’s regulatory landscape for human medicines. Among the most consequential changes are those affecting the legal basis and procedural requirements for Supplementary Protection Certificates (SPCs) and paediatric extensions.
In a January 2025 judgment, the Court of Appeal upheld the judgment of the High Court (Patents Court) in the case of Merck Serono S.A. (Appellant) v The Comptroller-General of Patents, Designs, and Trade Marks (Respondent).
On 16 December 2024, the High Court handed down its judgment in the case of Halozyme, Inc. v The Comptroller-General of Patents, Designs and Trade Marks.
In recent years, the convergence of beauty and pharmaceuticals has given rise to a new category of skincare products: cosmeceuticals. Cosmeceuticals blend cosmetic and pharmaceutical benefits and are designed to address skin complaints such as acne, dermatitis, and signs of aging.
The Court of Justice of the European Union has issued its long-awaited judgement on the interpretation of Articles 3(a) and (c) of the SPC Regulation in the joined cases C-119/22 and C-149/22.
The Central Division (Munich) has handed down a significant revocation decision in the ongoing patent battle between NanoString v 10x Genomics and President and Fellows of Harvard College.
The connection between IP and competition law may not be immediately obvious. However, it is important to bear in mind that competition law affects all commercial dealings, including intellectual property transactions.
AI's role in healthcare is expanding, enhancing diagnosis, treatment planning, administrative efficiency, and drug discovery. With the EU AI Act now in force, healthcare companies face an urgent need to ensure compliance.
The CJEU has handled the Hungarian referral in case C-181/24 with a straightforward confirmation that an application for a SPC must be based on the first marketing authorisation for the product.
If your next invention is going to have the commercial impact it should, you will need to correctly identify, protect, exploit, and enforce it. This is exactly what Potter Clarkson’s patent attorneys in Copenhagen do.
The Supreme Administrative Court in the Czech Republic has asked the CJEU whether a substance classified as an excipient in a marketing authorisation can still be considered an active ingredient for an SPC application, and what information is needed for an additional active ingredient to be "specifically identifiable" based on the patent.
We are delighted to report that our client, Proteotype Diagnostics Ltd, has just been awarded a £1.5 million Cancer Mission Grant to advance the groundbreaking work they have been doing in early cancer detection with their innovative Enlighten™ test.